Atezolizumab: observed
113 studies: patients on it are followed, or it is given outside a trial. Page 2 of 2. Open to participants first (49), then studies with results posted, then the rest; newest registration first within each.
- A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical PracticeCompletedNCT03782207Report a problem
- A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)CompletedNCT03645330Report a problem
- The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior ChemotherapyCompletedNCT03559647Report a problem
- Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReActionCompletedNCT03492242Report a problem
- Biomarkers of Immune-Related ToxicityActive, not recruitingNCT03409016Report a problem
- A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)TerminatedNCT03399643Report a problem
- Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse ReactionsCompletedNCT03387540Report a problem
- A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in ArgentinaCompletedNCT03330886Report a problem
- A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in ArgentinaCompletedNCT03321695Report a problem
- Study of Adverse Renal Effects of Immune Checkpoints InhibitorsCompletedNCT03316417Report a problem
- A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)CompletedNCT03232593Report a problem
- The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC PatientsStatus unknownNCT03228368Report a problem
- An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyApproved for marketingNCT02589717Report a problem